A Phase 3 interventional study of Pioglitazone and Glimepiride in Diabetes Mellitus, sponsored by Takeda. Completed at 79 sites in 4 countries. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 6 that started in 2003, is one of 31 in phase 3, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 35 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 6 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 547 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 16th largest by enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2003, is one of 45 in phase 3, and was the 2nd registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
Diabetes is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic and peripheral tissue cells to circulating insulin (ie, insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (ie, insulin deficiency due to beta-cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 21 million people have diabetes, with type 2 diabetes occurring in approximately 90% to 95% of cases. The goal of treating type 2 diabetes is to control blood glucose and thereby prevent long-term complications. Adequate glycemic control is paramount in attempting to avert chronic complications, including blindness; renal dysfunction resulting in dialysis or renal transplantation; neuropathy; non-traumatic amputations; and macrovascular complications, including myocardial ischemia and myocardial infarction, stroke, and peripheral arterial disease. Intensive glucose management in the early stages of diabetes may help forestall such complications.
Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes: decreased beta-cell function, elevated hepatic glucose output, and insulin resistance. Thiazolidinediones increase glucose utilization, decrease gluconeogenesis, and increase glucose disposal by binding to nuclear receptors known as peroxisome proliferator-activated receptors. Thiazolidinediones reduce insulin resistance by enhancing insulin sensitivity in muscle cells, adipose tissue, and hepatic cells (inhibiting hepatic gluconeogenesis), with no direct impact on insulin secretion. Thus, thiazolidinediones improve glycemic control and result in reduced levels of circulating insulin without predisposing patients to hypoglycemia. Peroxisome proliferator-activated receptors are found in tissues important for insulin action, such as adipose tissue, skeletal muscle, and the liver. The greatest concentration of peroxisome proliferator-activated receptors-gamma receptors is in adipose tissue.
This study was designed to compare the effects of pioglitazone compared to glimepiride on progression of atherosclerotic disease, as measured by intravascular ultrasound.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 547 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic criteria:
Target Coronary Artery:
Exclusion Criteria:
Was required to take or intended to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone
Drug: Glimepiride
Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Also known as: ACTOS®, AD4833
Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Nominal Change From Baseline in Percent Atheroma Volume
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.
Time frame: Baseline and Final Visit (up to 72 weeks)
Nominal Change From Baseline in Normalized Total Atheroma Volume
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.
Time frame: Baseline and Final Visit (up to 72 weeks)
Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section.
Time frame: Up to 72 weeks
Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section.
Time frame: Up to 72 weeks
Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section.
Time frame: Up to 72 weeks
Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure.
Time frame: Up to 72 weeks
Subjects were enrolled at 97 sites in the United States, Canada, Argentina and Chile from 21 July 2003 to 18 October 2007.
| Milestone | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Started | 274 | 273 |
| Completed | 177 | 178 |
| Not completed | 97 | 95 |
| Withdrew: Adverse event | 30 | 34 |
| Withdrew: Lack of efficacy | 4 | 1 |
| Withdrew: Lost to follow-up | 4 | 6 |
| Withdrew: Physician decision | 6 | 8 |
| Withdrew: Protocol violation | 6 | 3 |
| Withdrew: Withdrawal by subject | 40 | 34 |
| Withdrew: Other | 7 | 9 |
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.
| Percent volume | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Baseline | 40.592 ± 0.6925 | 40.016 ± 0.6663 |
| Nominal Change from Baseline | -0.161 ± 0.2095 | 0.725 ± 0.2017 |
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.
| Percent volume | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Baseline | 206.579 ± 7.2778 | 217.619 ± 7.0030 |
| Nominal Change from Baseline | -5.528 ± 1.5989 | -1.480 ± 1.5370 |
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section.
| Participants | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events | 5 (0 to 0) | 6 (0 to 0) |
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section.
| Participants | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events | 40 (0 to 0) | 41 (0 to 0) |
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section.
| participants | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events | 11 (0 to 0) | 13 (0 to 0) |
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure.
| Number of Events | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Nonfatal Myocardial Infarction | 2 | 4 |
| Nonfatal Stroke | 0 | 1 |
| Coronary Revascularization: PCI/CABG counted once | 29 | 30 |
| Coronary Revascularization: PCI | 25 | 28 |
| Coronary Revascularization: CABG | 5 | 2 |
| Carotid Endarterectomy/Stenting | 1 | 0 |
| Hospitalization for Unstable Angina | 4 | 2 |
| CHF Hospitalization: new/exacerbated counted once | 4 | 5 |
| Hospitalization for New CHF | 4 | 2 |
| Hospitalization for Exacerbated CHF | 0 | 3 |
| Noncardiovascular Mortality | 0 | 1 |
| Cardiovascular Mortality | 3 | 1 |
| Composite Endpoint A | 5 | 6 |
| Composite Endpoint B | 40 | 41 |
| Composite Endpoint C | 11 | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pioglitazone QD | — | — | — |
| Glimepiride QD | — | — | — |
| Event | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| Coronary Artery DiseaseCardiac disorders | 20/270 | 16/273 |
| Non-Cardia Chest PainGeneral disorders | 15/270 | 5/273 |
| Angina PectorisCardiac disorders | 8/270 | 4/273 |
| Coronary Artery StenosisCardiac disorders | 5/270 | 5/273 |
| Cardiac Failure CongestiveCardiac disorders | 3/270 | 5/273 |
| PneumoniaInfections and infestations | 0/270 | 5/273 |
| Angina UnstableCardiac disorders | 4/270 | 3/273 |
| Myocardial InfarctionCardiac disorders | 3/270 | 2/273 |
| Acute Coronary SyndromeCardiac disorders | 0/270 | 3/273 |
| Chronic Obstructive Airways Disease ExacerbatedRespiratory, thoracic and mediastinal disorders | 0/270 | 3/273 |
| Event | Pioglitazone QD | Glimepiride QD |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 41/270 | 100/273 |
| Oedema PeripheralGeneral disorders | 48/270 | 30/273 |
| Angina PectorisCardiac disorders | 12/270 | 30/273 |
| Weight IncreasedInvestigations | 28/270 | 15/273 |
| Non-Cardiac Chest PainGeneral disorders | 21/270 | 27/273 |
| DizzinessNervous system disorders | 26/270 | 20/273 |
| HypertensionVascular disorders | 13/270 | 24/273 |
| NasopharyngitisInfections and infestations | 13/270 | 22/273 |
| HeadacheNervous system disorders | 19/270 | 17/273 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 15/270 | 19/273 |
| Age, Categorical(Participants) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 189 | 193 | 382 |
| >=65 years | 81 | 80 | 161 |
| Sex: Female, Male(Participants) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Female | 84 | 93 | 177 |
| Male | 186 | 180 | 366 |
| Ethnicity (NIH/OMB)(Participants) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Hispanic or Latino | 63 | 71 | 134 |
| Not Hispanic or Latino | 207 | 202 | 409 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Native American | 3 | 10 | 13 |
| Asian | 12 | 16 | 28 |
| Black or African American | 30 | 27 | 57 |
| White | 225 | 220 | 445 |
| Family History of Coronary Artery Disease(Participants) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Male Relative History | 91 | 77 | 168 |
| Female Relative History | 60 | 59 | 119 |
| No Family History | 119 | 137 | 256 |
| Body Mass Index(Kg/m squared) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Mean | 32.08 ± 5.264 | 32.03 ± 5.233 | 32.05 ± 0 |
| Duration of Coronary Artery Disease(Months) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Mean | 40.4 ± 65.10 | 40.5 ± 67.20 | 40.4 ± 0 |
| Duration of Diabetes Mellitus(Months) | Pioglitazone QD | Glimepiride QD | Total |
|---|---|---|---|
| Mean | 98.0 ± 100.25 | 96.3 ± 89.51 | 97.1 ± 0 |
The record gives a start of Jul 2003, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone